{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Wet+Age-related+Macular+Degeneration&page=2",
    "query": {
      "condition": "Wet Age-related Macular Degeneration",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Wet+Age-related+Macular+Degeneration&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T15:20:53.227Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05381948",
      "title": "Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Wet Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "EYP-1901",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept 2mg/0.05mL Inj,Oph",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EyePoint Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 161,
      "start_date": "2022-06-30",
      "completion_date": "2024-04-24",
      "has_results": true,
      "last_update_posted_date": "2025-10-15",
      "last_synced_at": "2026-06-10T15:20:53.227Z",
      "location_count": 67,
      "location_summary": "Phoenix, Arizona • Springdale, Arkansas • Beverly Hills, California + 64 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05381948"
    },
    {
      "nct_id": "NCT01255774",
      "title": "Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Age Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The New York Eye & Ear Infirmary",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "51 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "51 Years to 90 Years"
      },
      "enrollment_count": 20,
      "start_date": "2007-06",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2011-12-05",
      "last_synced_at": "2026-06-10T15:20:53.227Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01255774"
    },
    {
      "nct_id": "NCT00058994",
      "title": "An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Degeneration",
        "Maculopathy, Age-Related"
      ],
      "interventions": [
        {
          "name": "anecortave acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2003-03",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2012-11-29",
      "last_synced_at": "2026-06-10T15:20:53.227Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00058994"
    },
    {
      "nct_id": "NCT01674569",
      "title": "Pilot Study of X-82 in Patients With Wet AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Exudative Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "X-82 oral",
          "type": "DRUG"
        },
        {
          "name": "ranibizumab (Lucentis)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tyrogenex",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2012-10",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2018-08-07",
      "last_synced_at": "2026-06-10T15:20:53.227Z",
      "location_count": 5,
      "location_summary": "Beverly Hills, California • New London, Connecticut • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "New London",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Abilene",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01674569"
    },
    {
      "nct_id": "NCT00499590",
      "title": "Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "bevasiranib",
          "type": "DRUG"
        },
        {
          "name": "ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 338,
      "start_date": "2007-08",
      "completion_date": "2009-05",
      "has_results": true,
      "last_update_posted_date": "2014-10-06",
      "last_synced_at": "2026-06-10T15:20:53.227Z",
      "location_count": 55,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Fresno, California + 47 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00499590"
    },
    {
      "nct_id": "NCT03954626",
      "title": "Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Age-Related Macular Degeneration",
        "Macular Degeneration",
        "Wet Macular Degeneration",
        "Retinal Degeneration",
        "Retinal Diseases",
        "Eye Diseases"
      ],
      "interventions": [
        {
          "name": "brolucuzumab 6 mg IVT",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2019-06-07",
      "completion_date": "2019-07-31",
      "has_results": true,
      "last_update_posted_date": "2021-01-05",
      "last_synced_at": "2026-06-10T15:20:53.227Z",
      "location_count": 2,
      "location_summary": "Phoenix, Arizona • Abilene, Texas",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Abilene",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03954626"
    },
    {
      "nct_id": "NCT02543229",
      "title": "Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Eye Diseases",
        "Macular Degeneration",
        "Retinal Diseases",
        "Retinal Degeneration",
        "Neovascularization, Pathologic"
      ],
      "interventions": [
        {
          "name": "OPT-302",
          "type": "DRUG"
        },
        {
          "name": "Lucentis™",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Opthea Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2015-07",
      "completion_date": "2017-09",
      "has_results": false,
      "last_update_posted_date": "2017-11-06",
      "last_synced_at": "2026-06-10T15:20:53.227Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Santa Maria",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02543229"
    },
    {
      "nct_id": "NCT01624636",
      "title": "Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "LFG316",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "55 Years to 90 Years"
      },
      "enrollment_count": 1,
      "start_date": "2012-12",
      "completion_date": "2013-05",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-06-10T15:20:53.227Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Winter Haven, Florida • Cleveland, Ohio",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Winter Haven",
          "state": "Florida"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01624636"
    },
    {
      "nct_id": "NCT01941082",
      "title": "A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "RO6867461",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2013-12",
      "completion_date": "2015-02",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-06-10T15:20:53.227Z",
      "location_count": 5,
      "location_summary": "Colorado Springs, Colorado • Baltimore, Maryland • Dallas, Texas + 2 more",
      "locations": [
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01941082"
    },
    {
      "nct_id": "NCT06184360",
      "title": "Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neovascular (Wet) Age-related Macular Degeneration"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2079,
      "start_date": "2022-05-31",
      "completion_date": "2022-12-16",
      "has_results": false,
      "last_update_posted_date": "2023-12-28",
      "last_synced_at": "2026-06-10T15:20:53.227Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06184360"
    }
  ]
}